NEW YORK--(BUSINESS WIRE)--The Klein Law Firm announces the commencement of an investigation of Solid Biosciences Inc. (NASDAQGS:SLDB) concerning possible violations of federal securities laws.
On March 14, 2018, Solid Biosciences issued a press release announcing receipt of a “notification from the U.S. Food and Drug Administration that IGNITE DMD, its Phase I/II clinical trial for SGT-001 microdystrophin gene transfer in Duchenne muscular dystrophy (DMD), has been placed on Clinical Hold.” Upon this news, shares of Solid Biosciences fell from a close of $26.31 on March 14, 2018 to a close of $9.32 on March 15, 2018.
If you suffered a loss in Solid Biosciences and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kkclasslaw.com/SLDB-Info-Request-Form-282.
Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
